Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal...

週六報告，因塞特宣佈第3期POD1Um-303/InterAACT2試驗中鉑金基化療方案（卡鉑-紫杉醇）聯合雷替伏單抗（Zynyz）用於無法手術治療的局部復發或轉移性鱗狀細胞肛門癌結果。

Benzinga · 09/16 17:23

Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal Carcinoma

Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel)
Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024

POD1Um-303/InterAACT2試驗的第三階段滿足了無進展生存期的主要終點，並證明了在接受鉑金化療（卡鉑-紫杉醇）的鱗狀細胞肛門癌（SCAC）患者中，使用retifanlimab聯合鉑金化療（卡鉑-紫杉醇）的療效有所改善。
在2024年歐洲醫學腫瘤學會（ESMO）大會上發佈的最新數據支持計劃於2024年底前提交美國補充生物製品許可申請（sBLA），申請retifanlimab用於鱗狀細胞肛門癌（SCAC）的治療。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。